Disease burden of ATTR amyloidosis based on the SF-36® health survey

Transthyretin (ATTR) amyloidosis is a progressive systemic disease associated with substantial morbidity and mortality. Although health-related quality of life (HRQoL) assessments are increasingly incorporated into clinical trials, data in ATTR amyloidosis remain limited. We conducted a retrospective observational study of patients with confirmed ATTR amyloidosis evaluated at the Boston University Amyloidosis Center between 1992 and 2022.